The category
What is life sciences
landscape intelligence?
Life sciences landscape intelligence is the practice of holding an entire therapeutic field as one connected, sourced picture: the companies, the programs, the clinical trials, the investors, and the partnerships between them, organized by the science rather than by industry category. It answers questions about a whole field, not about one record in it.
Last updated 2026-07-26
The work it replaces
Before it is a category, landscape intelligence is a task somebody does by hand. An analyst is asked which companies are developing against a given target, how far along they are, who financed them, and what happened to the programs that came before. The answer is assembled from five public sources, cross-referenced in a spreadsheet, and delivered as a deck. It takes somewhere between a week and a quarter depending on how wide the question is, and it begins going stale the day it is finished.
The category exists because that work is repeated constantly, by different people, over the same underlying facts, and because almost none of it is genuinely bespoke. What differs between two landscape requests is the question, not the source material.
What it is built from
Landscape intelligence is assembled from public primary sources. Nothing below is proprietary, which is why the discipline is reproducible and why the value is in the assembly rather than in exclusive access.
- Clinical trial registries
- ClinicalTrials.gov and its international equivalents. Who is running what, in which phase, against which endpoints, at which sites, and whether a trial is recruiting, completed, terminated, or quietly withdrawn.
- Regulatory filings
- S-1s, 10-Ks, 20-Fs, and 8-Ks. Where a private company's pipeline, licensing terms, milestone structures, and royalty obligations are stated in writing rather than in a press release.
- Trade press
- The daily biopharma newswire. Financings, licensing deals, M&A, readouts, discontinuations, and the personnel moves that precede all of them.
- Company releases
- Primary announcements, including the ones that never get picked up: an option exercised, a program deprioritized, a collaboration expanded.
- Scientific literature and patents
- Where a mechanism appears before it has a company attached, and where the founding science of a company can be traced back to a lab.
How it differs from adjacent tools
Landscape intelligence overlaps several established categories without being any of them. Each of the following answers a real question well. The distinction is scope: they are organized around one kind of record, and a landscape question crosses several.
- A pipeline database
- Answers what drugs exist against a target or indication, and at what phase. Deep on assets. Typically separate from who funded the company developing them and what the licensing terms were.
- A clinical trial database
- Answers who is running which trial, where, and with what design. Essential for operations and site selection. Not built to tell you who owns the asset or who financed it.
- A deal or financing database
- Answers who raised what, from whom, at what valuation. Strong on capital flows. Usually classifies a biotech by an industry tag rather than by indication, mechanism, or modality.
- Document search
- Answers what has been written, across filings, transcripts, and broker research. Excellent recall over text. Returns documents to read rather than a structured picture to query.
- A generalist company database
- Answers who a company is, who works there, and who invested. Built for every industry at once, so the fields that determine value in life sciences are not first-class.
| Category | Science | Trials | Money | Sources |
|---|---|---|---|---|
| Pipeline database | Covered | Not covered | Not covered | Not covered |
| Clinical trial database | Not covered | Covered | Not covered | Not covered |
| Deal or financing database | Not covered | Not covered | Covered | Not covered |
| Document search | Not covered | Not covered | Not covered | Covered |
| Generalist company database | Not covered | Not covered | Covered | Not covered |
| Landscape intelligence | Covered | Covered | Covered | Covered |
Who uses it
Business development and corporate development teams use it to find in-licensing and acquisition candidates, and to walk into a partnering meeting already knowing the counterparty's pipeline and deal history. Competitive intelligence and corporate strategy groups use it to maintain a standing picture of a therapeutic area rather than rebuilding one per request. Clinical development and medical affairs teams use it to see who else is recruiting against a mechanism and what happened to prior programs. Investors use it to source, to run diligence, and to track the fields they are already exposed to. Founders use it to target investors by what those investors have actually funded, and to watch the competitive field around their own program.
The common thread is that all of them are asking about a field rather than about a record, and all of them need to show their work afterwards.
The tools in this market
A neutral map of the established platforms whose coverage overlaps landscape questions. Descriptions and price ranges are drawn from the public sources listed at the foot of this page; treat them as indicative rather than quoted, since almost all of this market prices by negotiation.
| Platform | Primary coverage | Reported cost |
|---|---|---|
| Clarivate (Cortellis) | Pipeline, competitive, regulatory and deal intelligence suites. | Enterprise; reported at six figures annually for most module sets. |
| Citeline (Norstella) | Pharmaprojects for pipeline, Trialtrove for trials, Sitetrove for site selection. | Enterprise; reported six figures annually. |
| Evaluate | Consensus sales forecasts and portfolio analytics. | Enterprise; not publicly listed. |
| GlobalData | Broad cross-sector market intelligence with a pharmaceutical dataset. | Reported at roughly $30,000 to $80,000 a year. |
| AlphaSense | Search across filings, transcripts, broker research and expert calls. | Reported at roughly $10,000 to $100,000 a year per team. |
| IQVIA | Commercial, real-world and prescription data at scale. | Enterprise; multi-year contracts. |
Two things are visible in that table. The established platforms are priced for organizations with a procurement process, and most of them are organized around one kind of record: a pipeline, a trial, a document corpus, a prescription dataset. A team that wants a connected picture of a field generally licenses more than one and joins them by hand.
How to evaluate one
Six questions worth asking of anything in this category, including this one.
- 01
- Is it organized by the science or by an industry tag?
- Indication, mechanism of action, modality, phase and partnership status are the dimensions a life sciences question actually turns on. If they are filters rather than fields, most questions become keyword searches followed by manual work.
- 02
- Can you get from a fact to its source in one step?
- An answer you cannot attribute is an answer you cannot put in front of an investment committee. Ask to see the source and the exact sentence behind a specific relationship, not a bibliography for the platform.
- 03
- Does it connect the science to the money?
- Most tools own one domain well. The questions that take a week are the ones that cross domains: which investors backed programs against this mechanism, which Phase 2 assets have no partner, what happened to the last three companies that tried this.
- 04
- Does it keep the failures?
- A landscape without the discontinued programs is a misleading one. The most useful answer to "has anyone tried this" is often yes, and here is why it stopped.
- 05
- How current is it, and how do you know?
- Ask what triggers an update and how long the lag is between publication and appearance. A quarterly refresh and a continuous one are different products at the same price.
- 06
- What does it cost relative to the question you are asking?
- Published ranges run from a few thousand a year for narrow tools to six figures for enterprise suites. A team asking landscape questions a few times a quarter and a team running a portfolio need different things.
Where Terrane sits
Terrane is a landscape intelligence product. It reads the sources above continuously and resolves them into one connected map of companies, programs, trials, investors and partnerships, organized by indication, mechanism, modality, phase and licensing status, with the source and the exact sentence kept on every relationship it records.
It is pre-launch. Early access is open, and the figures shown across this site are illustrative placeholders rather than live data.
Sources
- Vendor coverage and reported price ranges: IntuitionLabs, “Overview of Pharmaceutical Market Intelligence Providers”, and Salesmotion, “Clarivate Alternatives”. Both accessed 2026-07-26.
- Primary sources named in this page are public: clinicaltrials.gov, sec.gov, pubmed.ncbi.nlm.nih.gov, fda.gov.
See your corner of the map.
Early access is open for life sciences investors, business development and strategy teams, competitive intelligence groups, and founders.